Evidence map›Paper›PMID 41901139›Full record

ReviewNutrients2026

Natural Products in the Metabolic and Endocrine Modulation of Polycystic Ovary Syndrome: Current Perspectives.

Siqi Liu, Rui Wang, Weili Yu, Chuanjing Shi, Xi Wang, Aifen Liu, Lei Zhang

Abstract readReview
In one paragraph

Review in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Siqi LiuInstitute of Interdisciplinary Integrative Medicine Research, School of Medicine, Nantong University, Nantong 226001, China.ORCID 0009-0007-3296-0064
Rui WangInstitute of Interdisciplinary Integrative Medicine Research, School of Medicine, Nantong University, Nantong 226001, China.ORCID 0009-0005-0023-6835
Weili YuInstitute of Interdisciplinary Integrative Medicine Research, School of Medicine, Nantong University, Nantong 226001, China.
Chuanjing ShiInstitute of Interdisciplinary Integrative Medicine Research, School of Medicine, Nantong University, Nantong 226001, China.ORCID 0009-0007-0725-7342
Xi WangInstitute of Interdisciplinary Integrative Medicine Research, School of Medicine, Nantong University, Nantong 226001, China.ORCID 0009-0000-3308-0455
Aifen LiuInstitute of Interdisciplinary Integrative Medicine Research, School of Medicine, Nantong University, Nantong 226001, China.ORCID 0009-0002-3086-4144
Lei ZhangInstitute of Interdisciplinary Integrative Medicine Research, School of Medicine, Nantong University, Nantong 226001, China.ORCID 0009-0003-8755-4283

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polycystic ovary syndrome (PCOS) is a prevalent endocrine and metabolic disorder, primarily characterized by reproductive dysfunction, insulin resistance (IR), and long-term metabolic complications. Current first-line pharmacological treatments, including oral contraceptives, anti-androgens, and insulin sensitizers, can alleviate clinical symptoms but often fail to fully address the underlying pathophysiology, and their long-term use is frequently limited by adverse effects. Natural products, owing to their multi-target regulatory properties and favorable safety profiles, have emerged a promising adjuvant therapeutic strategy. This review systematically summarizes how natural products exert beneficial effects through mechanisms such as improving metabolic homeostasis by enhancing insulin sensitivity and mitigating oxidative stress and chronic inflammation; restoring endocrine balance by modulating the hypothalamic-pituitary-gonadal axis to reduce hyperandrogenemia and promote ovulation; and utilizing emerging pathways including regulating gut microbiota homeostasis and epigenetic modifications as a novel avenue for PCOS drug development. Preclinical and clinical evidence collectively indicates that these agents hold significant translational potential to ameliorate metabolic disturbances and improve reproductive outcomes, providing a scientific foundation for future integrated intervention strategies in PCOS.

Indexed as

Biological ProductsPolycystic Ovary SyndromeAnimalsEpigenesis, GeneticFemaleGastrointestinal MicrobiomeHumansHypothalamic-Pituitary-Gonadal AxisInsulin ResistanceOxidative StressBiological Productsendocrine disordersepigenetic regulationgut microbiotainsulin resistancenatural productsPCOS

Identifiers

PMID41901139
PMCPMC13029731

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.